Analyst consensus rating
Akari Therapeutics Analyst Rating: none
Direct answer
Akari Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.50.
Forecast evidence checked September 17, 2026.
Get free Akari Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.12
- Average price target
- $28.50
- High price target
- $30.00
- Low price target
- $27.00
- Low target gap
- +166.8%
- Target upside
- +181.6%
- High target gap
- +196.4%
- Target range width
- 29.6%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- September 17, 2026
- Valid through
- September 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Akari Therapeutics?
Akari Therapeutics has a verified none consensus. The same dataset has an average price target of $28.50.
How far are Akari Therapeutics's low and high targets from the recorded price?
The low target implies +166.8%, while the high target implies +196.4%.
How many analysts are included in Akari Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Akari Therapeutics's target upside or downside calculated?
The average target of $28.50 is divided by the recorded price of $10.12, then one is subtracted to produce +181.6%. This does not guarantee a future return.
When was Akari Therapeutics's analyst forecast verified?
The data was verified on 2026-09-17. The dataset is valid through 2026-09-24.